Urszula Masiukiewicz, MD
Senior Director, Global Clinical Research and DevelopmentAbout
Titles
Senior Director, Global Clinical Research and Development
Biography
Dr. Urszula Masiukiewicz is an Assistant Clinical Professor of Medicine at Yale School of Medicine and an attending physician at Yale New-Haven Hospital. She obtained her medical degree from Warsaw Medical School, Warsaw, Poland, and completed postgraduate training at the National Institute of Cardiology in Warsaw, Poland and internal medicine residency at the University of Massachusetts-Memorial Medical Center, Worcester, Massachusetts. In 1996 Dr. Masiukiewicz joined Yale University as a fellow in endocrinology and rose to the rank of Assistant Professor. Dr. Masiukiewicz is a Senior Director in Cardiovascular and Metabolic Division at Pfizer, where she has conducted clinical research since 2004. Dr. Masiukiewicz is a part time clinical faculty member at Yale University and has clinical interests in postmenopausal osteoporosis, disorders of calcium metabolism, metabolic bone disease and thyroid disease.
Appointments
Endocrinology
Clinical InstructorPrimary
Other Departments & Organizations
Education & Training
- Fellow Hartford/NIA Center of Excellence
- Yale University School of Medicine (2000)
- Fellow
- Yale University School of Medicine (1999)
- Chief Medical Resident
- UMass Memorial Medical Center (1996)
- Resident
- Medical Center of Central Massachusetts (1995)
- Externship Residency
- UConn, New Britain General Hospital (1993)
- Resident
- National Institute of Cardiology (1988)
- MD
- Warsaw University (1985)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Urszula Masiukiewicz's published research.
Publications Timeline
A big-picture view of Urszula Masiukiewicz's research output by year.
Karl Insogna, MD, FACP
Barbara Gulanski, MD, MPH
James Revkin, MD, FACC, FACP, FCCP
19Publications
2,805Citations
Publications
2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, Investigators V. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal 2018, 206: 11-23. PMID: 30290289, DOI: 10.1016/j.ahj.2018.08.016.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedBlood GlucoseBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodEuropeFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsSurvival RateTreatment OutcomeUnited StatesConceptsAtherosclerotic cardiovascular diseaseCardiovascular outcome trialsCV deathHeart failureComposite outcomeOutcome trialsMajor adverse CV eventsStage 3 kidney diseaseType 2 diabetes mellitusEfficacy of ertugliflozinVERTIS-CV trialAdverse CV eventsNonfatal myocardial infarctionDouble-blind placeboPeripheral arterial diseaseCoronary artery diseasePeripheral arterial systemCV eventsERTugliflozin effIcacyNonfatal strokeRenal safetyDiabetes durationBaseline characteristicsRenal deathSerum creatinine
2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/nejmoa1701488.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAntibodiesAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLDouble-Blind MethodFemaleFollow-Up StudiesHumansHypercholesterolemiaInjections, SubcutaneousLipidsMaleMiddle AgedPCSK9 InhibitorsProprotein Convertase 9Risk FactorsTreatment FailureConceptsMajor cardiovascular eventsPrimary end pointHigh-risk patientsLDL cholesterol levelsCardiovascular eventsPlacebo groupCholesterol levelsMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolEnd pointSubtilisin kexin type 9Safety of bococizumabAdverse cardiovascular eventsHigh cardiovascular riskNonfatal myocardial infarctionLow-risk patientsInjection site reactionsHumanized monoclonal antibodyDifferent entry criteriaLonger duration trialsShort-duration trialsCardiovascular efficacyNonfatal strokeUrgent revascularizationCardiovascular death
2013
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal Of Medicine 2013, 369: 799-808. PMID: 23808982, DOI: 10.1056/nejmoa1302507.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute venous thromboembolismConventional therapy groupPrimary efficacy outcomeVenous thromboembolismMajor bleedingConventional therapyApixaban groupRelevant nonmajorEfficacy outcomesRecurrent symptomatic venous thromboembolismOral factor Xa inhibitorsFixed-dose regimenPrincipal safety outcomeSymptomatic venous thromboembolismDouble-blind studyFactor Xa inhibitorsOral apixabanAdverse eventsComposite outcomeRelative riskThromboembolismXa inhibitorsApixabanSafety outcomesBleeding
2004
- Masiukiewicz U, Insogna K. Calcium homeostasis and disorders of calcium metabolism during pregnancy and lactation. In Medical Complications During Pregnancy, 6th edition. Burrow G, Duffy T, editors.Books
2003
- Masiukiewicz U, Insogna K. Maternal calcium and skeletal homeostasis during pregnancy and lactation. In The DeGrooth Textbook of Endocrinology, DeGrooth L, Burrow G, editors. Endotext.org., 2003.Books
2002
Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAdultAnimalsBone and BonesBone ResorptionCollagenCollagen Type ICytokinesDisease Models, AnimalEstrogensFemaleFollow-Up StudiesHumansHyperparathyroidismInterleukin-6MenopauseMiceMiddle AgedOsteoporosis, PostmenopausalParathyroid HormonePeptidesPostmenopausePredictive Value of TestsPremenopauseReceptors, Interleukin-6Reference ValuesRetrospective StudiesConceptsIL-6/ILInterleukin-6Skeletal sensitivityPerimenopausal periodPrimary hyperparathyroidismPerimenopausal womenCytokine systemInterleukin-6 soluble receptorSerum IL-6 valuesEstrogen-deficient stateUrine N-telopeptideInterleukin-6/interleukinAction of PTHGroup of patientsIL-6 valuesSerum IL-6/ILEstrogen modulatesIL-6sRIL-6sR.Perimenopausal groupUrine NTXPremenopausal womenSkeletal complicationsCytokine profileExaggerated releaseEvidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
2001
IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo. Endocrinology 2001, 142: 3850-3856. DOI: 10.1210/en.142.9.3850.Peer-Reviewed Original ResearchCitationsConceptsCirculating levels of IL-6Levels of IL-6IL-11IL-6Circulating levelsBone resorptionSteady state mRNA levelsOsteoclast formationFive-day infusionHuman PTH-(1-84Pretreatment of cellsIL-11 levelsResponse to PTHIL-11 productionIncreased osteoclast formationIL-6 levelsPTH-(1-84Saos-2 cellsParathyroid adenomectomyDown-regulationProduction in vitroPrimary hyperparathyroidismPTH excessProduction in vivoSerum levels- 10. Nakchbandi I, Masiukiewicz U, Mitnick M, Grey A, Insogna K. Cytokines in Primary Hyperparathyroidism. In The Parathyroids 2nd edition. J. Belizikan, M Levine, R Marcus eds. Academic Press. 411-421, 2001Books
2000
Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*
Masiukiewicz U, Mitnick M, Grey A, Insogna K. Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*. Endocrinology 2000, 141: 2526-2531. DOI: 10.1210/en.141.7.2526.Peer-Reviewed Original ResearchConceptsCirculating levels of IL-6Levels of IL-6PTH-induced bone resorptionEstrogen-deficient stateIL-6Circulating levelsIL-6 productionPTH infusionEstrogen withdrawalBone resorptionResponse to PTH infusionChronic PTH excessEstrogen-replete conditionsTreated with PTHBone turnover markersInfusion of PTHBone resorption markersResponse to PTHEffect of PTHAbsence of estrogenRelease of IL-6Short-term infusionEstrogen-treated animalsInterleukin (IL)-6Collagen cross-linking
Academic Achievements and Community Involvement
activity Temporal Effects of Teriparatide on Bone Microarchitecture Assessed by High Resolution Peripheral Quantitative Computerized Tomography and Paired Bone Biopsies in Postmenopausal Women with Osteoporosis
Oral PresentationTemporal Effects of Teriparatide on Bone Microarchitecture Assessed by High Resolution Peripheral Quantitative Computerized Tomography and Paired Bone Biopsies in Postmenopausal Women with OsteoporosisDetails01/01/2009 - PresentDenver, CO, United StatesSponsored by American Society of Bone and Mineral Researchactivity . Temporal Changes in Bone Strength During 12 Months of Treatment with Teriparatide in Post-Menopausal Women with Osteoporosis
Oral Presentation. Temporal Changes in Bone Strength During 12 Months of Treatment with Teriparatide in Post-Menopausal Women with OsteoporosisDetails01/01/2009 - PresentDenver, CO, United StatesSponsored by American Society for Bone and Mineral Researchhonor Young Investigator Award
National AwardAmerican Society for Bone and Mineral ResearchDetails07/01/2000United Stateshonor Endocrine Fellows Foundation Research Award
National AwardEndocrine Fellows FoundationDetails07/01/1998United Stateshonor Hartford/NIA Center of Excellence in Aging
Regional AwardYale ResearchDetails07/01/1998United States
Links & Media
News
- June 16, 2022
Discoveries & Impact (June 2022)